Wilhelmy, F.; Hantsche, A.; Gaier, M.; Kasper, J.; Fehrenbach, M.K.; Oesemann, R.; Meixensberger, J.; Lindner, D. Tinzaparin vs. Nadroparin Safety and Efficacy in Neurosurgery. Neurol. Int.2021, 13, 202-206.
Wilhelmy, F.; Hantsche, A.; Gaier, M.; Kasper, J.; Fehrenbach, M.K.; Oesemann, R.; Meixensberger, J.; Lindner, D. Tinzaparin vs. Nadroparin Safety and Efficacy in Neurosurgery. Neurol. Int. 2021, 13, 202-206.
Wilhelmy, F.; Hantsche, A.; Gaier, M.; Kasper, J.; Fehrenbach, M.K.; Oesemann, R.; Meixensberger, J.; Lindner, D. Tinzaparin vs. Nadroparin Safety and Efficacy in Neurosurgery. Neurol. Int.2021, 13, 202-206.
Wilhelmy, F.; Hantsche, A.; Gaier, M.; Kasper, J.; Fehrenbach, M.K.; Oesemann, R.; Meixensberger, J.; Lindner, D. Tinzaparin vs. Nadroparin Safety and Efficacy in Neurosurgery. Neurol. Int. 2021, 13, 202-206.
Abstract
Background
An outbreak of African swine fever (ASF) in China in 2020 has led to an unprecedented shortage of fraxiparin. Most patients, especially those kept in hospital for surgery, are currently treated with prophylactic anticoagulation (AC). In search of alternatives for fraxiparin, we found no sufficient data on alternatives for neurosurgical patients, such as tinzaparin of European origin. We compared fraxiparin and tinzaparin concerning adverse events (bleeding versus thromboembolic events) in neurosurgical patients.
Methods
Between 2012 and 2018, 517 neurosurgical patients with benign and malignant brain tumors as well as 297 patients with subarachnoid hemorrhage (SAH) were treated in the Department of Neurosurgery, University Hospital Leipzig receiving prophylactic anticoagulation within 48 hours. In 2015, prophylactic anticoagulation was switched from fraxiparin to tinzaparin throughout the university hospital. In a retrospective manner, the frequency and occurrence of adverse events (rebleeding and thromboembolic events) in connection with the substance used was analyzed. Statistical analysis was performed using Fisher’s exact test and the chi-squared test.
Results
Rebleeding rates were similar in both fraxiparin and tinzaparin cohorts in patients being treated for meningioma, glioma, and SAH combined (8.8 vs 10.3%). Accordingly, the rates of overall thromboembolic events were not significantly different (5.5% vs 4.3%). The severity of rebleeding did not vary. There was no significant difference among subgroups when compared for deep vein thrombosis (DVT) or pulmonary embolism (PE).
Conclusion
In this retrospective study, tinzaparin seems to be a safe alternative to fraxiparin for AC in patients undergoing brain tumor surgery or suffering from SAH.
Medicine and Pharmacology, Neuroscience and Neurology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
,
,
